General Information:

Id: 122 (click here to show other Interactions for entry)
Diseases: Alzheimer disease - [OMIM]
Mammalia
review
Reference: Grimes CA and Jope RS(2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling Prog. Neurobiol. 65: 391-426 [PMID: 11527574]

Interaction Information:

Comment Lithium, the primary therapeutic agent for bipolar mood disorder, is a selective inhibitor of GSK3beta.
Formal Description
Interaction-ID: 494

drug/chemical compound

Lithium

decreases_activity of

gene/protein

GSK3B

Drugbank entries Show/Hide entries for Lithium or GSK3B
Comment Lithium activates the Wnt signaling pathway.
Formal Description
Interaction-ID: 570

drug/chemical compound

Lithium

increases_activity of

Drugbank entries Show/Hide entries for Lithium
Comment Lithium treatment resulted in decreased levels of Axin.
Formal Description
Interaction-ID: 583

drug/chemical compound

Lithium

decreases_quantity of

gene/protein

AXIN1

Drugbank entries Show/Hide entries for Lithium or AXIN1
Comment Lithium reduced tau phosphorylation.
Formal Description
Interaction-ID: 588

drug/chemical compound

Lithium

decreases_quantity of

protein modification

MAPT-phos

Drugbank entries Show/Hide entries for Lithium
Comment Abeta-induced neurotoxicity was reduced by antisense GSK3B oligonucleotides and by the GSK3B inhibitor lithium.
Formal Description
Interaction-ID: 864

drug/chemical compound

Lithium

affects_activity of

gene/protein

Amyloid beta peptide

Drugbank entries Show/Hide entries for Lithium
Comment Lithium reduced tau phosphorylation.
Formal Description
Interaction-ID: 64421

drug/chemical compound

Lithium

decreases_phosphorylation of

gene/protein

MAPT

Drugbank entries Show/Hide entries for Lithium